PARIS – For nearly four decades, mention of the Ebola virus has evoked death and terror, yet a simple factor – money – has stood in the way of erasing the curse, experts say.
Despite its evil reputation, Ebola breaks out only rarely in brief if murderous spurts in impoverished African countries.
That tiny — and poor — market means the disease has been a very low priority for Big Pharma, given the hundreds of millions of dollars it can take to devise a new drug or vaccine.
A Medecins Sans Frontieres (MSF) medical worker incinerates contaminated items after handling the body of an Ebola victim
Sylvain Baize, in charge of the Viral Haemorrhagic Fevers Reference Centre at France’s Pasteur Institute, said Ebola had claimed fewer than 2,000 lives in almost 40 years, a minute toll compared with other diseases.